OTC Markets OTCPK - Delayed Quote USD

Innate Pharma S.A. (IPHYF)

Compare

2.2450

0.0000

(0.00%)

At close: October 18 at 4:00 PM EDT

Currency in EUR All numbers in thousands

Download

Breakdown

TTM

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

Total Revenue

51,901.0000

49,580.0000

12,110.0000

56,155.0000

Cost of Revenue

3,042.0000

45,158.0000

Gross Profit

53,791.0000

23,815.0000

Operating Expense

64,570.0000

66,005.0000

59,937.0000

55,076.0000

Operating Income

-12,669.0000

-16,425.0000

-47,827.0000

1,079.0000

Net Non Operating Interest Income Expense

2,537.0000

258.0000

15.0000

223.0000

Other Income Expense

2,562.0000

-41,805.0000

2,330.0000

-2,131.0000

Pretax Income

-7,570.0000

-57,972.0000

-45,478.0000

-829.0000

Net Income Common Stockholders

-7,570.0000

-58,103.0000

-52,809.0000

-63,984.0000

Diluted NI Available to Com Stockholders

-7,570.0000

-58,103.0000

-52,809.0000

-63,984.0000

Basic EPS

-0.09

-0.73

-0.66

-0.81

Diluted EPS

-0.09

-0.73

-0.66

-0.81

Basic Average Shares

80,453.2820

84,111.1110

79,639.8260

79,542.6270

78,934.9600

Diluted Average Shares

80,453.2820

84,111.1110

79,639.8260

79,542.6270

78,934.9600

Total Operating Income as Reported

-12,669.0000

-57,425.0000

-47,825.0000

1,079.0000

Rent Expense Supplemental

1,702.0000

1,872.0000

Total Expenses

64,570.0000

66,005.0000

59,937.0000

55,076.0000

Net Income from Continuing & Discontinued Operation

-7,570.0000

-58,103.0000

-52,809.0000

-63,984.0000

Normalized Income

-10,132.0000

-16,167.0000

-47,808.0000

1,302.0000

Interest Income

3,177.0000

546.0000

327.0000

564.0000

Interest Expense

640.0000

288.0000

312.0000

341.0000

Net Interest Income

2,537.0000

258.0000

15.0000

223.0000

EBIT

-6,930.0000

-57,684.0000

-45,166.0000

-488.0000

EBITDA

-1,839.0000

-12,279.0000

-40,570.0000

56,309.0000

Reconciled Cost of Revenue

3,042.0000

45,160.0000

Reconciled Depreciation

5,091.0000

45,405.0000

4,596.0000

56,797.0000

Net Income from Continuing Operation Net Minority Interest

-7,570.0000

-57,972.0000

-45,478.0000

-829.0000

Total Unusual Items Excluding Goodwill

2,562.0000

-41,805.0000

2,330.0000

-2,131.0000

Total Unusual Items

2,562.0000

-41,805.0000

2,330.0000

-2,131.0000

Normalized EBITDA

-4,401.0000

29,526.0000

-42,900.0000

58,440.0000

12/31/2019 - 6/9/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

INCY.MX Incyte Corporation

1,292.00

0.00%

APLMW Apollomics, Inc.

0.0121

-12.95%

ABVX.PA ABIVAX Société Anonyme

9.63

+4.45%

APLM Apollomics, Inc.

0.1281

+3.98%

IVA.PA Inventiva S.A.

2.5000

+13.64%

TVGNW Tevogen Bio Holdings Inc.

0.0614

+53.50%

VRPX Virpax Pharmaceuticals, Inc.

0.6798

+9.28%

ZLAB Zai Lab Limited

27.49

+4.29%

INCY Incyte Corporation

66.39

-0.06%

ZEAL.CO Zealand Pharma A/S

804.00

+2.03%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Innate Pharma S.A. (IPHYF)

Upgrade to begin using 40 years of financial statements and get so much more.

Related Tickers